miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• MicroRNAs (miRNAs) play a role in tumor radiation resistance, a significant clinical challenge.
• Understanding miRNA function is crucial for developing effective cancer therapies.

Purpose of the Study:

• To identify and characterize the function of specific microRNAs involved in cancer radiation resistance.
• To elucidate the molecular mechanisms by which microRNAs confer radioresistance.

Main Methods:

• Investigated the role of miR-620 in cancer cell proliferation and cell cycle progression under radiation.
• Utilized gene expression analysis to identify direct targets of miR-620.
• Employed siRNA and exogenous prostaglandin E2 (PGE2) to assess radioresistance.
• Tested the effect of targeting the EP2 receptor on radioresistance.
• Conducted tumor xenograft experiments in vivo.

Main Results:

• miR-620 was found to increase cancer cell proliferation and decrease the G2/M cell cycle block, contributing to radiation resistance.
• HPGD (15-PGDH), a tumor suppressor gene, was identified as a direct target of miR-620.
• miR-620-mediated targeting of HPGD led to elevated prostaglandin E2 (PGE2) levels.
• siRNA-mediated HPGD knockdown or exogenous PGE2 administration mimicked radioresistance.
• Inhibition of the PGE2 receptor EP2 abrogated radioresistance.
• In vivo studies confirmed that miR-620 enhances tumor proliferation and radioresistance.

Conclusions:

• miR-620 confers radiation resistance in cancer cells by targeting the HPGD tumor suppressor gene.
• This mechanism leads to increased PGE2 levels, promoting proliferation and radioresistance.
• Targeting the miR-620/HPGD/PGE2 axis offers a novel therapeutic strategy for overcoming tumor radiation resistance.